Abstract

Objective

Inflammation plays a critical role in atherosclerosis. This study examines the effects of ticagrelor and clopidogrel on inflammatory parameters, obtained from complete blood count (CBC) and biochemical measurements, in patients with acute coronary syndrome.

Methods and Results

One hundred acute coronary syndrome (ACS) patients were included in the study and grouped according to clopidogrel (n = 50) or ticagrelor (n = 50) usage as an anti-aggregant (with acetylsalicylic acid). All patients underwent percutaneous coronary intervention. On admission, at third- and sixth-month after ACS, white blood cell (WBC) count, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-high-density lipoprotein ratio (MHR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were calculated from the CBC and biochemical measurements. NLR, PLR, and SII were significantly lower in the ticagrelor group (p < 0.001, at 3rd and 6th month). Also, MHR was lower in the ticagrelor group (p < 0.05). Conversely, WBC count was higher in the ticagrelor group (p < 0.001).

Conclusions

NLR, MHR, PLR, and SII levels were lower in ACS patients treating with ticagrelor. Ticagrelor may improve these inflammatory parameters in percutaneous coronary intervention (PCI)-treated ACS patients compared to clopidogrel.

中文翻译：

---

替格瑞洛改善急性冠脉综合征患者的全身免疫炎症指数

摘要

客观的

炎症在动脉粥样硬化中起着关键作用。本研究检查了替格瑞洛和氯吡格雷对急性冠脉综合征患者炎症参数的影响，这些参数通过全血细胞计数 (CBC) 和生化测量获得。

方法和结果

100 名急性冠脉综合征 (ACS) 患者被纳入研究，并根据氯吡格雷 ( n  = 50) 或替格瑞洛 ( n  = 50) 作为抗凝血剂（与乙酰水杨酸）的使用情况进行分组。所有患者均接受经皮冠状动脉介入治疗。入院时，ACS 后第 3 个月和第 6 个月时，检测白细胞 (WBC) 计数、中性粒细胞与淋巴细胞比值 (NLR)、单核细胞与高密度脂蛋白比值 (MHR)、血小板与淋巴细胞比值(PLR) 和全身免疫炎症指数 (SII) 是根据 CBC 和生化测量值计算的。替格瑞洛组的 NLR、PLR 和 SII 显着降低（p  < 0.001，第 3 个月和第 6 个月）。此外，替格瑞洛组的 MHR 较低 ( p < 0.05)。相反，替格瑞洛组的 WBC 计数更高 ( p  < 0.001)。

结论

在接受替格瑞洛治疗的 ACS 患者中，NLR、MHR、PLR 和 SII 水平较低。与氯吡格雷相比，替格瑞洛可以改善经皮冠状动脉介入治疗 (PCI) 治疗的 ACS 患者的这些炎症参数。